Items Tagged ‘keytruda’

October 17th, 2017

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

By

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A recently published study has demonstrated that patients with earlier stage III, locally advanced NSCLC may benefit from anther checkpoint inhibitor Imfinzi […]

View full entry

Tags: checkpoint inhibitor, durvalumab, Imfinzi, immunotherapy, keytruda, locally advanced NSCLC, Lung Cancer, News, nivolumab, opdivo, pembrolizumab, Precision Cancer Medicine


October 12th, 2017

Immunotherapy Active Against Triple-Negative Breast Cancer

By

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), […]

View full entry

Tags: atezolizumab, Breast Cancer, checkpoint inhibitor, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, Tecentriq, Triple Negative Breast Cancer


October 4th, 2017

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is […]

View full entry

Tags: 2016, advanced, ESMO, keytruda, Lung Cancer, News, Non-Hodgkin's Lymphoma, nsclc, opdivo, PD-1, pembrolizumab, Tecentriq


September 25th, 2017

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

By

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy and, in some cases, HER2/neu-targeted […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, Gastric Cancer, gastro-esophogeal junction cancer, keytruda, metastatic gastric, News, pembrolizumab, Precision Cancer Medicine


September 18th, 2017

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

By

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer […]

View full entry

Tags: Gastric Cancer, immunotherapy, KEYNOTE-059 programmed death-ligand 1, keytruda, metastatic gastric cancer, News, PD-L1, pembrolizumab, Precision Cancer Medicine, stomach cancer


August 14th, 2017

Head and Neck Cancer-What You Need to Know

By

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck cancers account for about 3 percent of […]

View full entry

Tags: checkpoint inhibitors, Head and Neck Cancer, human papilloma virus, keytruda, News, opdivo, PD-1, Throat Cancer


July 6th, 2017

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients

By

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone, […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, News, nivolumab, nsclc, opdivo, Precision Cancer Medicine


June 15th, 2017

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) report that Keytruda is now associated with a 30% improvement in survival when used as initial treatment for advanced […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, PD-1, pembrolizumab, precison medicine, Yervoy


June 9th, 2017

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer

By

The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly threefold in patients with triple-negative […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, keytruda, News, opdivo, PD-1, precision medicine, Triple negative Breast Cancer (TNBC), Yervoy


May 11th, 2017

FDA Approval Suggests Keytruda® Combined With Chemotherapy May Become New Standard Initial Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 precision cancer medicine, in combination with Alimta®  (pemetrexed) and carboplatin chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for […]

View full entry

Tags: keytruda, Lung Cancer, News, nsclc, PD-1, precision cancer immunotherapy


April 4th, 2017

Keytruda Shows Promise in Treatment of Mesothelioma

By

Keytruda (pembrolizumab), an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published in The Lancet Oncology, is the first […]

View full entry

Tags: keytruda, Mesothelioma, News


March 23rd, 2017

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

By

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20 percent of cancers diagnosed worldwide. The trial is called DART, […]

View full entry

Tags: All Cancer Types, General, immunotherapy, keytruda, Neuroblastoma, News, Other News Topics (not Types of Cancer), Retinoblastoma, Sarcoma, Vaginal Cancer


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


October 25th, 2016

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such as Keytruda […]

View full entry

Tags: fda, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab